BioXcel Therapeutics, Inc. (BTAIQ): Total Liabilities
$140.38M
As of 2025-12-31
$144.26M
As of 2026-06-30
+2.8%
3-year compound annual growth
+60.4%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $140.38M | +6.8% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $131.44M | +0.9% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $130.21M | +0.9% | 2025-03-28, Balance as of period end |
| 2022-12-31 | $129.08M | +626.3% | 2024-03-22, Balance as of period end |
| 2021-12-31 | $17.77M | +34.2% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $13.24M | +39.4% | 2022-03-11, Balance as of period end |
| 2019-12-31 | $9.50M | +103.8% | 2021-03-12, Balance as of period end |
| 2018-12-31 | $4.66M | +99.4% | 2020-03-09, Balance as of period end |
| 2017-12-31 | $2.34M | n/a | 2019-03-12, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | $140.38M | +6.8% |
| Polomar Health Services, Inc. (PMHS) | 2025-12-31 | $1.61M | +19.2% |
| Vaccinex, Inc. (VCNX) | 2024-12-31 | $5.08M | -14.4% |
| PMGC Holdings Inc. (ELAB) | 2025-12-31 | $5.03M | +115.6% |
| Lexaria Bioscience Corp. (LEXX) | 2025-08-31 | $1.57M | +30.1% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $2.40M | -83.8% |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $69.14M | +0.8% |
| Quantum Cyber N.V. (QUCY) | 2025-12-31 | $4.69M | -37.6% |
| Lipella Pharmaceuticals Inc. (LIPO) | 2024-12-31 | $754.4K | +74.3% |
Compare BTAIQ, PMHS, VCNX, ELAB side by side · Screen every company in Pharmaceutical Preparations ↗